ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
HIT Consultant: Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care
Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, recently spoke with HIT Consultant about why the conventional genomic test commonly used for breast cancer treatment planning is failing Black women, and in part, contributing to their disproportionately high mortality rate. Dr. Johnson discusses why MammaPrint provides more consistent results for Black women than the other gene expression profiling test, enabling more personalized treatment and improved outcomes. Read the Article
Fierce Healthcare: Biden’s ‘Cancer Moonshot’ is already being fueled by tech addressing breast cancer
Fierce Healthcare recently spoke with Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, about the need for more widespread use of advanced gene expression profiling tests that provide more consistent results for Black women with early-stage breast cancer. Dr. Johnson highlights how the standard of care today negatively impacts outcomes for Black women, and why it is essential for clinicians to switch to more sophisticated, unbiased tests, such as MammaPrint & BluePrint, to address key disparities in breast cancer care. Read the Article
News
Media Releases
Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
At the 2023 ASCO Annual Meeting, Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, will present data that proves MammaPrint can predict chemotherapy sensitivity in women with early-stage, HR+HER- breast cancer. . Read the Article
Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapyTrial reinforces Agendia’s progress in developing practice-changing evidence to improve personalized cancer careMarch 16, 2023 Read More
Updated NCCN® Guidelines Recognize MammaPrint® UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates
Includes level one evidence that MammaPrint can help prevent unnecessary chemotherapy¹ and endocrine therapy² Confirms Agendia’s unique ability to identify tumors that have a very low risk of distant metastasis which can have implications for Read More
Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients
Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrint’s ability to identify strongest candidates for extended endocrine therapy among HR+HER2- post-menopausal women December 08, 2022 09:00 AM Eastern Standard Time Read More
